

TAKEDA ONCOLOGY IS COMMITTED TO THE ADVANCEMENT OF INNOVATIVE THERAPIES: ONCOLOGY DEVELOPMENT PIPELINE

PROGRAM	DESCRIPTION	DISEASE(S) UNDER INVESTIGATION	PHASE 1	PHASE 2	PHASE 3
BRENTUXIMAB VEDOTIN¹	CD30 Antibody Drug Conjugate	Hodgkin Lymphoma, Cutaneous T-Cell Lymphoma, Peripheral T-Cell Lymphoma, Anaplastic Large Cell Lymphoma			
BRIGATINIB	ALK Inhibitor	Non-Small Cell Lung Cancer			
IXAZOMIB	Proteasome Inhibitor	Multiple Myeloma, Amyloidosis			
PEVONEDISTAT	Nedd8-Activating Enzyme Inhibitor	High-Risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, Low-Blast Acute Myelogenous Leukemia Solid Tumors			
PONATINIB²	BCR-ABL Inhibitor	Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia			
VEDOLIZUMAB	Anti- α 4 β 7 Antibody	Graft versus Host Disease			
SAPANISERTIB (TAK-228)	TORC1/TORC2 Inhibitor	Endometrial Cancer Solid Tumors			
TAK-659	SYK/FLT-3 Inhibitor	Lymphoma			
TAK-931	CDC7 Inhibitor	Pancreatic Cancer, Colorectal Cancer Solid Tumors			
CABOZANTINIB³	MET, VEGF, AXL and RET Inhibitor	Renal Cell Carcinoma, Hepatocellular Carcinoma			
ALISERTIB	Aurora A Inhibitor	Acute Myeloid Leukemia			
NIRAPARIB⁴	PARP Inhibitor	Ovarian Cancer			
TAK-788	EGFR/HER2 Inhibitor	Non-Small Cell Lung Cancer			
TAK-573	CD38-targeted IgG4 fused with attenuated IFN α	Multiple Myeloma			
TAK-164	Anti-guanlyl cyclase C antibody drug conjugate	Pancreatic Cancer, Colorectal Cancer			
TAK-079	Anti-CD38 antibody	Multiple Myeloma			
TAK-981	SUMO Inhibitor SAE	Solid Tumors			

All programs have Global Development Rights unless otherwise noted.

¹ Brentuximab vedotin is co-developed by Takeda and Seattle Genetics, Inc. ² Takeda shares development rights with Incyte (Europe, Turkey and Israel) and Otsuka (Asia Pacific territories).

³ Japan Only. ⁴ Niraparib is being developed under a licensing agreement with Tesaro, Inc. for all tumor types in Japan and all tumor types excluding prostate cancer in South Korea, Taiwan, Russia and Australia.

